跨性别患者微创子宫切除术后阴道残端裂开
本研究为单术者回顾性队列分析,比较2015年1月至2021年12月间接受微创子宫切除术的跨性别患者与顺性别患者的阴道残端裂开(VCD)发生率。49例跨性别患者中3例(6.1%)发生VCD,117例顺性别患者中2例(1.7%)发生,差异未达统计学显著;跨性别组均为自发性裂开,顺性别组均有可识别的诱发因素。作者提出睾酮暴露可能是VCD的危险因素,但不能排除年轻等其他因素。
要点
- 跨性别患者微创子宫切除术后VCD发生率为6.1%(3/49),顺性别患者为1.7%(2/117),差异未达统计学显著。
- 跨性别组VCD均为自发性且可识别危险因素少,顺性别组VCD均有可识别的诱发因素(如创伤)。
- 作者提出睾酮暴露可能是VCD的危险因素,但不能排除年轻等其他因素。
核心结论
- 跨性别患者接受微创子宫切除术可能VCD风险增加,但该并发症罕见,本研究数据未能确定统计学显著性。
- 作者提出睾酮暴露可能是VCD的可能危险因素,但不能排除年轻等其他因素驱动该人群VCD。
- 需未来对生物标本进行研究以评估这些患者的细胞差异。
研究设计与样本
- 单术者回顾性队列分析,比较2015年1月至2021年12月期间由研究术者行微创子宫切除术的性别肯定与其他指征(良性、恶性、预防性)患者的VCD发生率。
- 研究地点为美国一家大型城市学术三级护理医院。
- 共166例患者符合纳入标准,其中49例(29.5%)因性别肯定行微创子宫切除术。
- 其余117例中,92例(78.6%)因癌症、15例(12.8%)因预防性、10例(8.5%)因良性指征行微创子宫切除术。
主要发现
- 跨性别患者手术时 tended to be younger,但两组人口学特征其他方面相似。
- 大多数跨性别患者(n=36,73.5%)在子宫切除术时切除双侧卵巢,100%术前和术后接受睾酮治疗,无人使用补充雌激素。
- 49例跨性别患者中3例(6.1%)发生术后阴道残端裂开,117例顺性别患者中2例(1.7%)发生,差异未达统计学显著。
- 描述性分析显示,顺性别组所有裂开病例均有可识别的诱发因素(即创伤),而跨性别组所有裂开病例均为自发性且可识别危险因素少。
临床怎么用
- 原文未据此给出推荐。
- 作者认为跨性别患者接受微创子宫切除术可能VCD风险增加,但该并发症罕见,本研究数据未能确定统计学显著性。
- 作者提出睾酮暴露可能是VCD的可能危险因素,但不能排除年轻等其他因素。
- 作者指出需未来对生物标本进行研究以评估这些患者的细胞差异。
局限性
- 该并发症罕见,本研究数据未能确定统计学显著性。
- 不能排除其他因素(如年轻)作为该人群VCD的驱动因素。
- 需未来对生物标本进行研究以评估这些患者的细胞差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To compare rates of vaginal cuff dehiscence (VCD) in transgender patients with cisgender patients after minimally invasive hysterectomy (MIH). DESIGN: We performed a single-surgeon, retrospective cohort analysis comparing the rates of VCD in patients undergoing MIH for gender affirmation with other indications (benign, malignant, prophylactic) with our study surgeon between January, 2015, and December, 2021. SETTING: Major, urban, academic tertiary care hospital in the United States. PATIENTS: 166 patients met inclusion criteria with 49 of those patients undergoing MIH (29.5%) for gender affirmation. Of the remaining 117 patients, 92 (78.6%) underwent MIH for cancer, 15 (12.8%) for prophylaxis, and 10 (8.5%) for benign indications. INTERVENTIONS: Not applicable. MEASUREMENTS: We assessed included patients for baseline demographics, presence of risk factors for VCD, details of index hysterectomy, and details of cuff dehiscence events. MAIN RESULTS: Transgender patients tended to be younger at the time of surgery, but demographics were otherwise similar between both groups. Most transgender patients (n = 36, 73.5%) had both ovaries removed at the time of hysterectomy, 100% were on testosterone therapy pre- and postoperatively, and none used supplementary estrogen. Three of the 49 transgender patients (6.1%) experienced postoperative dehiscence of the vaginal cuff compared with 2 of the 117 cisgender patients (1.7%). This failed to reach statistical significance; however, our descriptive analysis showed that all cases of dehiscence in the cisgender group had identifiable precipitating factors (i.e., trauma). By comparison, all cases of dehiscence in the transgender group were spontaneous with few identifiable risk factors. CONCLUSION: Transgender patients undergoing MIH may be at increased risk of VCD, although the rarity of this surgical complication precluded determination of statistical significance in our data set. We propose testosterone exposure as a possible risk factor for VCD, although we cannot exclude other factors, such as young age, as drivers of VCD in this population. Future studies of biospecimens are needed to evaluate for cellular differences in these patients.
引用
- O'Connor RM, Scott ME, Rimel BJ, et al. Vaginal Cuff Dehiscence in Transgender Patients After Minimally Invasive Hysterectomy. J Minim Invasive Gynecol. 2023. PMID: 37925016. doi:10.1016/j.jmig.2023.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。